Collegium Pharmaceutical's Engagement in Upcoming Investor Conferences
As investors gear up for a busy conference season, Collegium Pharmaceutical, Inc. (Nasdaq: COLL) is poised to showcase its commitment to innovation at several key industry events. The management team is excited to connect with investors and share their vision for future growth and patient-centric solutions.
Participation in Major Healthcare Conferences
Jefferies London Healthcare Conference
One of the highlights on Collegium's schedule is the Jefferies London Healthcare Conference. This engaging event is set for a Wednesday morning, featuring a live presentation from the company’s leadership at 8:00 a.m. GMT. Attendees can look forward to insights into the company's strategic objectives and pipeline developments.
Piper Sandler 37th Annual Healthcare Conference
Following the London event, Collegium will also participate in the Piper Sandler Healthcare Conference. Scheduled for the afternoon of December 2, this fireside chat will offer another platform for Collegium’s executives to engage with investors and discuss the transformative potential of its products. Important details about this event will be accessible through the company's investor segment on their official website.
Evercore Healthcare Conference
The company will round out its conference participation at the Evercore Healthcare Conference, where attendees can gain further understanding of Collegium's strategic direction. This event promises to provide valuable insights as Collegium positions itself within the evolving pharmaceutical landscape.
About Collegium Pharmaceutical, Inc.
Collegium is dedicated to building a diversified biopharmaceutical enterprise with a primary focus on enhancing the quality of life for individuals suffering from serious medical conditions. The company is particularly renowned for its comprehensive portfolio of responsible pain management therapies, fostering improved patient outcomes. Among its flagship offerings is Jornay PM®, which represents a groundbreaking advancement in ADHD treatment.
Guided by a clear growth strategy, Collegium is not only expanding its commercial lineup but also committing to responsible investment choices. Their headquarters in Stoughton, Massachusetts, lends a strong presence in the biopharmaceutical sector, and the company's dedication to patient care is evident through its innovative solutions.
For further records and updates on Collegium’s activities, investors and stakeholders are encouraged to visit their official website, where they keep a repository of archived presentations. These are particularly useful for those unable to attend the live sessions due to scheduling conflicts.
Investor Contacts
Collegium highly values communication with its investor community. The key contacts for investor relations are:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com
Danielle Jesse
Director, Investor Relations
ir@collegiumpharma.com
Frequently Asked Questions
What is Collegium Pharmaceutical known for?
Collegium Pharmaceutical specializes in biopharmaceuticals, focusing on pain management and neuropsychiatry treatments, with Jornay PM® being a significant product in their portfolio.
When will Collegium's presentations take place?
Collegium will present at the Jefferies London Healthcare Conference on November 19 and the Piper Sandler conference on December 2.
How can I access the webcasts of these conferences?
Webcasts of the conferences can be accessed through the Investors section on Collegium's corporate website.
Who can I contact for investor relations inquiries?
For inquiries, you can reach out to Ian Karp or Danielle Jesse, whose contact emails are available in the investor relations section of the Collegium website.
What strategies is Collegium pursuing for growth?
Collegium aims to expand its commercial portfolio and utilize responsible capital deployment to enhance patient care and treatment solutions in their market segments.